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Abstract: Nanoparticles (NPs) have been widely explored for delivering doxorubicin (DOX), an
anticancer drug, to minimize cardiotoxicity. However, their efficiency is marred by a necessity
to chemically modify DOX, NPs, or both and low deposition of the administered NPs on tumors.
Therefore, alternative strategies should be developed to improve therapeutic efficacy and decrease
toxicity. Here we report the possibility of employing a monolithic nanoporous gold (np-Au) rod as
an implant for delivering DOX. The np-Au has very high DOX encapsulation efficiency (>98%) with
maximum loading of 93.4 mg cm−3 without any chemical modification required of DOX or np-Au.
We provide a plausible mechanism for the high loading of DOX in np-Au. The DOX sustained release
for 26 days from np-Au in different pH conditions at 37 ◦ C, which was monitored using UV-Vis
spectroscopy. Additionally, we encased the DOX-loaded np-Au with rapamycin (RAPA)-trapped
poly(D,L-lactide-co-glycolide) (PLGA) to fabricate an np-Au@PLGA/RAPA implant and optimized
the combinatorial release of DOX and RAPA. Further exploiting the effect of the protein corona
around np-Au and np-Au@PLGA/RAPA showed zero-order release kinetics of DOX. This work
proves that the np-Au-based implant has the potential to be used as a DOX carrier of potential use in
cancer treatment.
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1. Introduction
Doxorubicin (DOX), an anthracycline anticancer drug, has been known for its effectiveness in treating a wide variety of cancers, including breast cancer, ovarian cancer, Kaposi’s
sarcoma, and lymphomas [1–3]. It is a DNA intercalating agent and works primarily by
inhibiting the progression of an enzyme called topoisomerase II [4]. However, its use as a
cancer drug has been severely constrained due to its inability to distinguish cancer cells
from normal cells, resulting in life-threatening side effects [5]. One of the most serious
side effects of DOX is congestive heart failure [6]. It has been found that the rate of cytotoxicity depends on the cumulative dose. Therefore, efforts have been made to improve
the targeted drug delivery systems (DDSs) to selectively detect and destroy cancer cells
using nanostructures as a carrier [7–9]. The most notable nanocarrier for DOX is based on
liposomes, where DOX is encapsulated inside the liposomes and delivered to cancer cells
through the enhanced permeability and retention effect (EPR) [1]. The PEGylated form of
liposomes has been approved by the US Food and Drug Administration (FDA) for treating
ovarian cancer and Kaposi’s sarcoma after failure of prior systematic chemotherapy [10].
The non-PEGylated form has been approved in Europe and Canada for treating metastatic
breast cancer. Although encapsulating DOX inside these liposomes has significantly reduced the cardiotoxicity, many severe side effects of DOX remained, including hand-foot
syndrome, anemia, and oral cancer [11,12].
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To improve nanocarrier-based DOX delivery, a variety of other organic and inorganic
nanoparticles are the subject of current research. However, due to many prerequisites for
the nanocarrier to be considered safe and effective, none of the other formulations have
been clinically approved for delivering DOX. Besides being biocompatible, the nanocarriers
must have prolonged blood circulation to accumulate in the tumor microenvironment [13].
The other important challenges for the advancement of nanocarrier-based DDS are an
aggregation of nanocarriers, premature release of drugs in the normal extracellular environment, adsorption of protein on the surface of nanocarriers, clearance from the renal
system, capture by the mononuclear phagocytic system (MPS), the fate of nanocarriers after
releasing a drug, and toxicity caused by buildups of nanocarriers in visceral organs [14–16].
Moreover, it has been found that only 0.7% (median) of the nanoparticles from the administered dose reach a solid tumor via the EPR mechanism [17]. This is a serious problem when
trying to translate cancer-targeting nanoparticles from small animal models to humans.
For example, it increases cost and complexity to scale up the production of nanoparticles
required to administer a high dose and toxicity due to an interaction of >99% of administered nanoparticles with off-target tissues. Therefore, there is a need to address DOX
delivery methods from different perspectives.
Implants present great possibilities for effectively treating a variety of localized cancers. It allows both non-site-specific and site-specific sustained release of the drug, which
can continuously attack cancer cells while significantly lowering dose-related systemic
side effects of the drug. The need for localized therapy of cancer in order to minimize sideeffects has been reviewed [18]. In the site-specific implantation, it drastically lowers the
toxicity to distant normal cells. It can be easily implanted at the desired location through an
implant applicator or image-guided delivery method with minimal incision. The usage of
an implant also helps to improve patient compliance by reducing the frequency of dosing.
Varieties of biocompatible materials are explored for designing suitable implants and are
generally chosen based on either chemical inertness (e.g., silicone) or biodegradable properties (e.g., PLGA) [19]. These materials have their strengths and weaknesses in terms of
physical robustness, chemical inertness, drug loading, release kinetics, and biocompatibility.
Diverse types of implants are clinically approved for treating varieties of cancers, most
notably for prostate cancer and brain tumors. Prostate cancer can be treated with a high
dose of radiation by implanting radioactive seeds (also called brachytherapy) directly in
the microenvironment of the prostate tumor [20]. On the other hand, brain tumors can be
effectively treated by implanting a carmustine-containing wafer in the brain after surgical
removal of a tumor [21]. However, studies for the sustained release of DOX from implants
for effective treatment of cancers are limited, mainly because of the drug resistance by
the cancer cells. It has been reported that when DOX is given in combination with the
rapamycin (RAPA), an immunosuppressive drug, its effectiveness in treating cancer significantly increases [22–24]. There is a growing interest in developing implants that are
made of porous nanostructured materials [25–27]. Examples of materials under development as non-eroding implants include nanoporous anodic alumina, titania nanotubes, and
mesoporous silica. The use of these materials provides a means of avoiding burst release
associated with biodegradable implant polymers and these materials are also selected as
biocompatible, stable, inert, and of high surface area. They do not swell or disintegrate,
which is sometimes a desirable property. The control of material properties can be used to
obtain sustained release and to alter the release profile by adjusting pore dimensions or by
surface modification. For a number of these materials, external stimuli such as magnetic
fields or ultrasound can be used to modulate drug release. Applications to orthopedics,
coronary stents, and release of cancer drugs are all under active investigation. As emphasized by Seker and coworkers [28–30] and by Shih and coworkers [31], nanoporous gold is
also of interest as a material for drug release applications. The biomedical and bioanalytical
applications have also been reviewed by these authors [32].
Herein, we demonstrated that a nanoporous gold (np-Au) millirod coated with RAPA
containing PLGA (np-Au@PLGA/RAPA) is a promising implant for a sustained, controlled,
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RAPA containing PLGA (np-Au@PLGA/RAPA) is a promising implant for a sustained,
controlled, and parallel release of DOX and RAPA (Scheme 1). The np-Au millirod is a
monolithic
nanostructure
of gold
bicontinuous
pores
and ligaments
with a 3D
reand parallel3D
release
of DOX and
RAPAhaving
(Scheme
1). The np-Au
millirod
is a monolithic
markably
high of
surface
area to volume
ratio [33].
Furthermore,
thewith
np-Au
is biocompatible
nanostructure
gold having
bicontinuous
pores
and ligaments
a remarkably
high
and
chemically
inert with
tunable
pores sizes and
Seker’s lab and
has previously
surface
area to volume
ratio
[33]. Furthermore,
thevolumes
np-Au is[34].
biocompatible
chemically
envisioned
the possibility
of using
as DDS
thehas
effect
of the ionic
environinert with tunable
pores sizes
andnp-Au
volumes
[34]. studying
Seker’s lab
previously
envisioned
the possibility
of using
np-Au as DDS studying
the effect
of theHere
ionicwe
environment
on the
ment
on the release
of surface-immobilized
fluorescein
[28,29].
show that np-Au
release
of surface-immobilized
fluorescein
Here
show that
np-Au hasofexcellent
has
excellent
DOX encapsulation
efficiency[28,29].
without
anywe
chemical
modification
DOX or
DOX encapsulation
without
any kinetics
chemicalofmodification
of DOX
or np-Au.
We
np-Au.
We have alsoefficiency
found that
the release
DOX from np-Au
is pH
dependent
have
found
thehand,
releasePLGA
kinetics
DOX from np-Au
pH dependent material
at 37 ◦ C. apOn
at
37 also
°C. On
thethat
other
is of
a biocompatible
andisbiodegradable
the otherbyhand,
PLGA
biocompatible
biodegradable
material into
approved
by acid
the FDA
proved
the FDA
asisa adrug
carrier [35].and
It degrades
by hydrolysis
glycolic
and
as a drug
[35].trapped
It degrades
by hydrolysis
into
glycolic
acid
releasing
lactic
acidcarrier
releasing
RAPA.
The goal of
this
research
is and
not lactic
to testacid
whether
the
trapped
RAPA.
The
goal
of
this
research
is
not
to
test
whether
the
released
drugs
kill
cancer
released drugs kill cancer cells in animal models, but to explore interfaces and interactions
cells
in animal
but toDOX
explore
andcontrols
interactions
of np-Au
with unmodified
of
np-Au
with models,
unmodified
andinterfaces
how np-Au
the release
mechanism.
ThereDOXwe
and
how
controls
the release
mechanism.
Therefore,
did
not
perform
fore,
did
notnp-Au
perform
any experiment
using
animal models
or cellwe
lines
but
focused
on
any experiment
cell linesgold
but focused
on examining the
vitro
examining
the inusing
vitro animal
release models
kinetics.or
However,
and its nanostructures
are in
known
release
However,
gold[36–38].
and its Gold
nanostructures
known
for their[39]
biocompatible
for
theirkinetics.
biocompatible
nature
coating of are
medical
implants
has become
nature
[36–38].
Gold
coating
of
medical
implants
[39]
has
become
a
fairly
common
a fairly common practice. Nanoporous gold electrodes are being developed forpractice.
neural
Nanoporous[40–43].
gold electrodes
are demonstrate
being developed
for neural stimulationis[40–43].
Our
stimulation
Our results
that np-Au@PLGA/RAPA
a promising
results
demonstrate
that
np-Au@PLGA/RAPA
is
a
promising
candidate
for
the
co-release
candidate for the co-release of DOX and RAPA, which can have promising applications
of cancer
DOX and
RAPA, which can have promising applications in cancer treatment.
in
treatment.

Scheme 1.
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2. Materials and Methods
2.1. Materials and Reagents
White gold round wire (10K, 24 GA) was purchased from Hoover and Strong (Richmond, VA, USA). It is an alloy of 41.8% gold and 58.2% of proprietary ratios of nickel,
copper, and zinc. Poly(D, L-lactide-co-glycolide) (PLGA, lactide:glycolide = 65:35, MW
= 40,000–75,000) and rapamycin (RAPA, ≥95%) were purchased from Sigma–Aldrich
(St. Louis, MO, USA). Doxorubicin hydrochloride (DOX) was purchased from TCI America and newborn calf serum was purchased from ThermoFisher Scientific. Antibiotics
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(Penicillin/streptomycin), solvents (HPLC grade), and buffers were obtained from SigmaAldrich. Ultrapure water (18.2 MΩ.cm at 25 ◦ C) was prepared using a Simplicity UV
system from Millipore Corporation.
2.2. Preparation of np-Au Millirods
The np-Au millirods were prepared by submerging 5 mm long gold alloy wires
(diameter = 0.51 mm) in concentrated HNO3 for 24 h at room temperature [44]. This process
selectively removes other reactive metals from alloy creating a bicontinuous network of
pores and ligaments of gold. As-prepared np-Au millirods were thoroughly rinsed with
milli-Q water and stored in ethanol until further use.
2.3. Surface Area Estimation of np-Au
The surface area of the np-Au millirod was estimated using cyclic voltammetry
(CV). The experiment was carried out using PARSTAT 2273 potentiostat (EG&G Princeton
Applied Research) in a three-electrode setup with Ag/AgCl (KCl sat.) as a reference
electrode and coiled platinum wire (diameter = 0.5 mm) as a counter-electrode. The np-Au
millirod was fixed on a gold electrode using 2.0 µL of 0.5 wt % Nafion to be used as working
electrode. The potential during CV was cycled between 0.0 and +1.6 V at the scan rate
of 5 mV s−1 in 0.5 M H2 SO4 at room temperature. The charge under the oxide reduction
peak of cyclic voltammogram was used to estimate the surface area of np-Au using the
conversion factor of 450 µC cm−2 [45].
2.4. Surface Morphology and Composition of np-Au
The surface morphologies of np-Au were studied using a scanning electron microscope
(SEM 6320F)(JEOL USA, Inc., Peabody, MA, USA) at an acceleration voltage of 8 kV. The
ligament’s width and interligament gap of np-Au were computed using analySIS (Soft
Imaging System GmbH, Munster, Germany). The purity of np-Au implants after dealloying
was determined using an energy-dispersive X-ray (EDX) detector (Oxford Instruments,
Abingdon, UK) coupled to SEM.
2.5. Loading of DOX Inside np-Au
To study the effect of pH on DOX loading inside np-Au, a low concentration of DOX
(25 µM) was prepared in acetate buffer (pH 5.5), milli-Q water, and tris buffer (pH 7.4).
A high concentration of DOX (1 mM) was prepared in pH 5.5 acetate buffer because of
its higher solubility in acidic conditions. The np-Au implants were submerged in DOX
solution in centrifuge or microcentrifuge tubes and left in the dark at room temperature
for 24 h with gentle shaking. The wires were washed with fresh buffer after loading. The
amount of DOX loaded in np-Au was calculated by subtracting the absorbance peak at
480 nm before and after loading (UV–Vis spectrophotometer, Cary 50) (Figure S1) and
fitting with a standard curve (Figure S2). The encapsulation efficiency (EE) of DOX was
determined using the following equation
EE (%) =

Amount of DOX loaded in np-Au
× 100%
Total amount of DOX

2.6. Atomic Force Microscopy (AFM) Imaging
Atomic force microscopy (AFM) images were collected in tapping mode for characterizing the morphology of np-Au before and after DOX loading, and the corresponding height
distribution profiles were plotted to determine the changes in height. BioScope ResolveTM
AFM (Bruker, Santa Barbara, CA, USA) integrated with NanoScope® software and silicon
cantilevers TAP300Al-G (Ted Pella, INC, Redding, CA, USA) with a force constant of
40 N/m were used for imaging. The images were processed using Gwyddion software.
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2.7. Fourier Transform Infrared (FTIR) Spectroscopy
DOX loaded inside np-Au was extracted using pure dimethyl sulfoxide (DMSO) for
checking any structural modification of DOX inside np-Au. Then, the DOX was dried at
40 ◦ C by passing nitrogen gas overnight and FTIR-attenuated total reflection (ATR) spectra
were collected over the range 4000–650 cm−1 at a resolution of 2 cm−1 using NICOLET
6700 spectrometer (Thermo Fisher Scientific, Waltham, MA, USA).
2.8. Computations
Energy minimization and molecular orbital energy calculation were carried out using
ChemBio3D Ultra.
2.9. Coating of DOX-Loaded np-Au with PLGA/RAPA Film
The PLGA and RAPA were separately dissolved in dichloromethane (DCM) and
DMSO, respectively, to prepare 10% (w/w) solutions. They were then thoroughly mixed to
create 0.5% (w/w) of RAPA in PLGA. The as-prepared PLGA/RAPA mixture was used for
dip coating DOX-loaded np-Au. The DOX-loaded np-Au was submerged and rolled for
15 s in the 100 µL PLGA/RAPA mixture in a microcentrifuge tube followed by drying at
37 ◦ C overnight. The loss of DOX during the 15 s of dip-coating is considered as negligible
mainly because it is a quick process, the PLGA is highly viscous, and DOX that might come
out of np-Au should be trapped within the PLGA layer. SEM imaging was performed to
determine the thickness of the PLGA layer around the np-Au implant.
2.10. In Vitro Drugs Release Kinetics
For the study of in vitro release, drug-loaded np-Au implants with or without a coating
of PLGA/RAPA were incubated in a capped glass vial containing 5 mL of release media
at 37 ◦ C. We used four different types of environments as release media: pH 5.5 (acetate
buffer), pH 6.6 (phosphate buffers), pH 7.4 (phosphate buffer), and 10% newborn calf serum
containing 1% penicillin/streptomycin. At predetermined time intervals, 500 µL of the
supernatant was removed and the same volume of fresh medium was added. The collected
supernatant containing DOX and RAPA was quantified using UV–Vis spectrophotometer
at 480 nm and 279 nm, respectively (Figures S1 and S2).
3. Results and Discussion
3.1. Fabrication and Characterization of np-Au Millrods
The np-Au millirods were prepared by leaching the reactive metals from Au alloy
millirods by submerging in concentrated HNO3 for 24 h. The specific surface area of the
as-prepared np-Au was determined by cyclic voltammetry using the gold oxide-stripping
method and found to be 6.04 ± 0.54 m2 g−1 (Figure 1). This value is comparable (6.4 m2 g−1 )
to our previous work when determined using the BET surface area analysis [46]. For
implants, it is appropriate to express specific surface area as per unit volume rather than
mass and was found to be 25.53 m2 cm−3 . This high surface area-to-volume ratio of np-Au
millirod is advantageous for loading higher amount of drug molecules. The inset (i) of
Figure 1 shows a change in the metallic color of Au alloy to dark color after dealloying
indicating the formation of nanopores. The inset (ii) of Figure 1 is the magnified CV of the
Au electrode, the surface area of which is negligible compared to the surface area of np-Au.
The surface morphology of the np-Au millirod was characterized using SEM (Figure 2A–B’).
We found that the surface morphology varied between the top (exterior) and cross-sectional
(interior) regions of np-Au. The exterior surface is crack-free over wide regions with minor
scratches on the surface, whereas the interior surface has small domains of structures
oriented at different angles due to different crystal planes. The bright regions in the
low magnification cross-sectional SEM image are caused by mechanical breakage during
sample preparation. However, neighboring darker structures were not affected by the
mechanical force due to different crystal orientations. The high magnification SEM images
show the characteristic bicontinuous structure of np-Au with ligaments and interligament
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gaps consistent with previous reports [47]. We found that the interior region has larger
ligament widths and interligament gaps compared to the exterior region (Figure 3). The
Nanomaterials 2021, 11, x FOR PEER REVIEW
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The surface morphology of the np-Au millirod was characterized using SEM (Figure
2A–B’). We found that the surface morphology varied between the top (exterior) and
cross-sectional (interior) regions of np-Au. The exterior surface is crack-free over wide
regions with minor scratches on the surface, whereas the interior surface has small domains of structures oriented at different angles due to different crystal planes. The bright
regions in the low magnification cross-sectional SEM image are caused by mechanical
breakage during sample preparation. However, neighboring darker structures were not
affected by the mechanical force due to different crystal orientations. The high magnification SEM images show the characteristic bicontinuous structure of np-Au with ligaments
and interligament gaps consistent with previous reports [47]. We found that the interior
region has larger ligament widths and interligament gaps compared to the exterior region
(Figure 3). The measurements were taken at right angles to the length of ligaments and
gaps for the ligament width and interligament gap, respectively. The average ligament
width and interligament gap of the exterior region are 24 ± 6 nm and 26 ± 5 nm, respectively, whereas those for the interior region are 39 ± 10 nm and 33 ± 8 nm, respectively.
The EDX spectra in Figure 4 illustrate that the np-Au is free from reactive metals present
in the alloy.
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Figure 2. SEM images of top view (A,A’) and cross-sectional view (B,B’) of np-Au millirod at7low
(A,B) and high (A’,B’) magnifications. Letters a and b in figure (B’) represent typical ligament
width and interligament gaps, respectively.
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DOX did not play a significant role in the loading process. Furthermore, it was found
that the presence of 0.14 M NaCl significantly increased the loading capacity under all
the experimental pH conditions. This further suggests that electrostatic interactions of
NH3 + with the gold surface are not the dominant factor for determining DOX loading. The
pKa value of the primary amine on DOX is reported as 8.2 [48]. The addition of NaCl will
diminish unfavorable electrostatic interactions between DOX molecules and hence it is
reasonable that at these pH values below the pKa where the amine group is to some extent
protonated that the addition of NaCl would favor higher loading over that found in the
absence of NaCl if interactions between DOX molecules are the dominant factor. Addition
of NaCl also prevented DOX from degrading or changing when acetate buffer was used as
a loading buffer (Figure S3). Attempts to use a basic condition (pH 8.4) were unsuccessful
because of the low solubility of DOX at a basic pH where the amine group is unprotonated.
The loading being the highest in water with NaCl is perhaps due to a lack of interference of
buffer ions that may also adsorb on the gold surface to some extent when a buffer is used.
The zeta potential of Au was reported on the basis of streaming potential measurements on
vacuum sputtered thin gold films to be near −20 mV for the range pH = 6–8 when the pH
Nanomaterials 2021, 11, x FOR PEER REVIEW
9 of 20
was adjusted using only KOH or HCl at an ionic strength of 10−3 M [49]. The isoelectric
point of the Au surface was reported to be at pH = 4.5.
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tion is to improve the loading rate while minimizing the waste. As shown in Figure 6B,
the loading efficiency of np-Au millirod is close to 100%, when it was incubated in 0.1 mL
DOX solution for 24 h. However, maximum loading was obtained from 0.2 mL DOX solution with a loading efficiency of 89%, which is 95.5 ± 0.5 µg per np-Au millirod. Further
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loading rate while minimizing the waste. As shown in Figure 6B, the loading efficiency
of np-Au millirod is close to 100%, when it was incubated in 0.1 mL DOX solution for
24 h. However, maximum loading was obtained from 0.2 mL DOX solution with a loading
efficiency of 89%, which is 95.5 ± 0.5 µg per np-Au millirod. Further increasing the volume
of DOX to 0.3 mL did not significantly improve the loading efficiency. The loading of DOX
in a PLGA millirod of dimensions d = 1.5 mm and L = 8 mm was reported as 2900 µg [50].
If the np-Au millirod of the same size was prepared and loaded as described then 1450 µg
of DOX would be incorporated assuming an equivalent outcome. The loading of the np-Au
is in the same range of magnitude and could be increased by reducing the pore size. It has
been reported that dealloying of a thin alloy film precursor gave nanoporous gold with
an average pore size of 28 nm when done at room temperature and that average pore size
was reduced to 15 nm by dealloying at 0 ◦ C and to 7 nm by dealloying at −20 ◦ C for the
same 4 h period [51]. The reduction of the average pore size by decreasing the temperature
of dealloying would provide a means to increase the surface area and hence increase the
Nanomaterials 2021, 11, x FOR PEERloading
REVIEW capacity if so desired. The effect of altering pore size on loading capacity
10and
of 20
kinetics and on release kinetics remains an area for further study.
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3.4. Effect of DMSO on Loading of DOX
DMSO has been frequently used to dissolve and internalize DOX in different nanocarriers [52]. Interestingly, we did not observe any loading of DOX inside the np-Au millirod
when DMSO was used as a solvent. DMSO is well-known for accepting protons and
breaking hydrogen-bonds [53], which implies that hydrogen bonding is a crucial force for
the loading of DOX inside np-Au. DMSO may block the loading of DOX on np-Au by
interacting with DOX, np-Au, or both, eventually breaking up hydrogen-bonding. FTIR
spectra in Figure 8 correspond to solid samples of pure DOX (blue) and DOX extracted
from np-Au four weeks after loading (red). The pure DOX shows characteristic peaks at
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Figure 6. Loading of different volumes of 1 mM DOX on np-Au at pH 5.5. (A) Photographic image
of original DOX (left) and after 24 h loading on np-Au from 0.1, 0.2, and 0.3 mL DOX solution. (B)
Amount of DOX loaded on np-Au from a different volume.
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3.4. Effect of DMSO on Loading of DOX
DMSO has been frequently used to dissolve and internalize DOX in different
nanocarriers [52]. Interestingly, we did not observe any loading of DOX inside the np-Au
millirod when DMSO was used as a solvent. DMSO is well-known for accepting protons
and breaking hydrogen-bonds [53], which implies that hydrogen bonding is a crucial force
for the loading of DOX inside np-Au. DMSO may block the loading of DOX on np-Au by
interacting with DOX, np-Au, or both, eventually breaking up hydrogen-bonding. FTIR
spectra in Figure 8 correspond to solid samples of pure DOX (blue) and DOX extracted
from np-Au four weeks after loading (red). The pure DOX shows characteristic peaks at
3523.61 cm−1 (O-H stretch), 3318.02 cm−1 (O-H and N-H stretch), and 1731 cm−1 (C=O
stretch) [54]. Most of the peaks of the extracted DOX were similar to that of the pure DOX
except the disappearance of the peak at 3523.61 cm−1 and broadening of the peak at 3318.02
Figure 7. Typical atomic force microscopy (AFM) topographic images of np-Au before (A) and
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right.

Figure 8.
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Figure
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spectra
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3.5. Mechanism
of DOX
on np-Au
3.5.
MechanismofofLoading
Loading
of DOX
on np-Au
In general,
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the DOX
DOX molecules
molecules are
are loaded
loaded on
on the
the surface
surface of
ofgold
goldnanostructures
nanostructures through
In
through
intermediate
organic
molecules
by
either
covalent
or
electrostatic
interactions
intermediate organic molecules by either covalent or electrostatic interactions
[55,56]. You
[55,56]. You et al. reported a very high payload of DOX on citrate-capped hollow gold
nanospheres and claimed that it was due to electrostatic interactions between positively
charged DOX molecules and negatively charged citrates on the surfaces of nanospheres
[57]. However, Curry et al. reported that DOX can directly interact with AuNPs through
the Au+–π interaction and Au+–carbonyl coordination by displacing citrate on the surface
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et al. reported a very high payload of DOX on citrate-capped hollow gold nanospheres
and claimed that it was due to electrostatic interactions between positively charged DOX
molecules and negatively charged citrates on the surfaces of nanospheres [57]. However,
Curry et al. reported that DOX can directly interact with AuNPs through the Au+ –π
interaction and Au+ –carbonyl coordination by displacing citrate on the surface of gold
nanoparticles [58]. The Au+ ions on the surface of AuNPs are believed to be available due
to the binding of AuCl2 − complexes on the surface of AuNPs during synthesis [58,59]. In
contrast, there is a low possibility of forming such a complex on the surface of an np-Au
Nanomaterials 2021, 11, x FOR PEER REVIEW
12 of 20
millirod, as we employed the top-down fabrication strategy. Nevertheless, we still observed
a high loading of DOX in the np-Au millirod. Therefore, it is imperative to understand the
forces that help the exceptional loading of DOX inside np-Au.
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environment
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In DOX,
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carbonyl interaction is highly likely along with the Au–π for loading of DOX on np-Au.
At low DOX concentration (25 µM), we found two distinct loading kinetics at all the
three pH conditions, relatively faster loading for the initial 4 days constituting 50% of the
total loading and then slower loading kinetics from 5 to 14 days. It is reasonable to say
that the first loading step involves only adsorption of DOX on Au, as DOX does not tend
to form dimers at low concentration. When a complete monolayer is formed on the np-Au
surface, the process of dimerization starts slowly as the unbound DOX approach the surface-bound DOX leading to π–π stacking [63,64]. Finally, an intermolecular network of
hydrogen bonding interactions occurs stabilizing the dimer. At high DOX concentration
(1 mM), on the other hand, maximum loading was achieved within 24 h supporting the
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drying and dip-coating steps. However, the release rate of DOX drastically decreased with
(1 mM), on the other hand, maximum loading was achieved within 24 h supporting the
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fact that dimerization occurs quickly after the interaction of DOX with Au. However,
at a very high concentration, it is also possible that DOX dimerize first in the solution
followed by adsorption on the Au surface. To this end, more work needs to be done to
better understand the exact mechanism.
3.6. PLGA/RAPA Coating
The DOX-loaded np-Au was encapsulated by PLGA containing RAPA using the dipcoating method for combined release of DOX and RAPA. PLGA is well-known for the
entrapment of diverse types of therapeutics, and its drug releasing capabilities can be easily
tuned by varying its molecular wt., ratio of lactide to glycolide, and size/thickness [65].
We found that single dip-coating creates nearly 1.5 µm thick PLGA coating around np-Au
implant, as shown in Figure 10. Multiple dip-coatings can be created by repeating drying
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Figure 9. Electrostatic potential surface of HOMO and LUMO of DOX in the front and side view.
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6.9) and hence would be advantageous for release of DOX. Most of the DOX released at
37 °C under the experimental pH conditions is due to the disruption of a network of intermolecular hydrogen bonding and π–π stacking releasing the monomeric DOX. This is
important as non-monomeric DOX, such as a dimer, cannot effectively interact with DNA
the way monomeric DOX can do [10]. Delivering nanoparticles containing high concenFigure10.
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cross-section
np-Au@PLGA/RAPA
obtained
single
coatFigure
ofof
np-Au@PLGA/RAPA
obtained
byby
single
dipdip
trationsSEM
of DOX directly
inside tumor cells
always creates the chance
of dimerization
ifcoating.
ing. The thickness of PLGA coating is ≈1.5 µm. Scale bar:10 µm.
Theburst
thickness
of PLGA
coating
is ≈1.5 µm. Scale bar:10 µm.
released,
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3.7. In Vitro Drug Release
The release behavior of DOX from np-Au and np-Au@PLGA/RAPA was assessed
mimicking possible physiological conditions. It was monitored at 37 °C in buffer solutions
at three different pH values (5.5, 6.6, and 7.4) and in newborn calf serum at pH 7.4. The
release profiles of DOX from np-Au and np-Au@PLGA/RAPA in buffer at different pH
are shown in Figure 11A,B, respectively. At all the pH conditions, DOX released from both
np-Au and np-Au@PLGA/RAPA showed sustained release for more than 3 weeks. It can
also be seen that a higher percentage of DOX released with lower pH conditions. This is
important as the extracellular microenvironments of tumor cells is slightly acidic (pH 6.5–

Figure 11. Cumulative release of drugs as a function of time. (A) DOX from np-Au in buffers at different pH, (B) and (C)

Figure 11. Cumulative release of drugs as a function of time. (A) DOX from np-Au in buffers at different pH, (B) and
DOX and RAPA, respectively, from np-Au@PLGA/RAPA in buffers at different pH, and (D) DOX from np-Au and np(C) DOX
and RAPA, respectively,
from
np-Au@PLGA/RAPA
in buffers at different pH, and (D) DOX from np-Au and
Au@PLGA/RAPA
in newborn calf
serum
(NBCS) at pH 7.4.
np-Au@PLGA/RAPA in newborn calf serum (NBCS) at pH 7.4.
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half of
the that
total amount of drug released is reached. After that, the release rate reverses with
increasing pH (7.4 < 6.6 < 5.5), leading to the cumulative release of 26, 34, and 37%,
respectively, in 25 days. The former process can be linked to the effect of pH on
breaking hydrogen bonding whereas the latter can be associated with increased
solubility of DOX at low pH. On the other hand, we found that DMSO can burst release
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the rate is faster at higher pH (7.4 > 6.6 > 5.5) until nearly half of the total amount of drug
released is reached. After that, the release rate reverses with increasing pH (7.4 < 6.6 <
5.5), leading to the cumulative release of 26, 34, and 37%, respectively, in 25 days. The
former process can be linked to the effect of pH on breaking hydrogen bonding whereas the
latter can be associated with increased solubility of DOX at low pH. On the other hand, we
found that DMSO can burst release ≈100% of the DOX loaded on np-Au millirod within an
hour. This is due to the strong interaction of DMSO with both gold [66] and DOX breaking
hydrogen bonds.
Unlike in np-Au, the initial burst release of DOX was not observed for np-Au@PLGA/
RAPA. This is due to the PLGA coating over np-Au, which not only efficiently blocks the
burst release but also slows down the release rate in a controlled manner. This leads to
similar release rates under all the three pH conditions until nearly half of the total amount
of drug released is reached. Then the release rates vary significantly under different pH
conditions with the low pH condition having a slow release rate.
Although the drug delivery system based only on pure PLGA structures is widely
explored, it is still not a perfect system. The major drawback of the PLGA-based delivery
system is the high initial burst release [67]. Weinberg and coworkers have shown that the
vast majority of DOX loaded inside PLGA implant releases within 24 h with the half-time
of ~4 h [50]. In this study, the effect on tumor size was evaluated on day 4 and day 8
after implantation. Using PLGA and np-Au together significantly decreased burst release
behavior. The time frame for release of DOX from PLGA depends on the form of PLGA,
its molecular weight, and chemical modification of the polymer end groups. The time
frames for release studies from PLGA was similar to that followed here for DOX release
from np-Au of 26 days. The release of DOX from PLGA microspheres with either acid or
ester end groups and molecular weights of 17 or 44 Da was compared over a six-week
period [68]. The ester-capped PLGA microspheres showed release with an initial burst
phase, followed by a lag phase of several days and an accelerated release phase while
the acid-capped PLGA microspheres showed only burst release mostly completed within
7 days. While the release of near 90% was observed from the acid-capped PLGA, release
near only 45% was observed for ester-capped PLGA microspheres. DOX conjugated to the
end of PLGA by ester linkage and formed into nanoparticles showed a sustained release
over a month that was slower for PLGA of molecular weight 10,000 Da than for molecular
weight of 5000 Da. In contrast, DOX not conjugated to PLGA burst release within 5 days
from DOX/PLGA nanoparticles (d = 200 nm) [69]. The release of DOX from porous PLGA
microspheres (d ~ 10 mm) prepared using water-in-oil-in-water emulsions was followed
over a 20-day period and nearly 70% was released in combination with paclitaxel [70]. The
release of DOX from PLGA microparticles prepared by spray drying was studied and for
varied lactide content a burst release was observed with 70% of the drug released within a
day. When composite microparticles were prepared with a variable composition of PLGA
and poly-L-lactide (PLLA), it was found that 36–48% of DOX was released within the first
half hour followed by slower release monitored over a period of 12.5 days [71]. Additional
features of the use of PLGA microparticles in drug delivery and release have recently
been reviewed [72].
The release of RAPA from np-Au@PLGA/RAPA occurs simultaneously with the
DOX, Figure 11C. It starts with the initial burst release, which can be attributed to a quick
release of the surface embedded RAPA, followed by sustained release. Although the rate
of erosion of PLGA by hydrolytic degradation is the crucial factor controlling the release
of RAPA, other multiple factors are actively involved including diffusion of RAPA from
PLGA and swelling of PLGA. The release of DOX from np-Au along the PLGA matrix can
also contribute to the release of RAPA.
A key point is that the use of an implant is intended to provide localized therapy
where the drug diffuses out of the implant and the localized concentration in and near
the tumor tissue is of key importance. It is actually desired to reduce the systemic distribution to minimize side effects that would occur if DOX was injected intravenously.
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The therapeutic dose of DOX depends on many factors including the nature and the size
of the tumor. The recommended dosage of DOX by the U.S. FDA is 60–75 mg m−2 or
1.2–2.4 mg kg−1 , as an intravenous injection administered at 21 days interval. However,
how much of this drug reaches tumor sites in humans is still a subject of research. In
a mouse model, 1 ng DOX mg−1 of tumor has been reported for DOX injected without
any carrier and up to 4–25 ng DOX mg−1 for a tumor with liposomes when 5 mg kg−1 of
DOX was administered [73,74]. Although this depends on various factors, DOX in the ng
range is sufficient to suppress tumor growth [73]. Therefore, the loading amount of 100 µg
per np-Au millirod in our study is significant because (1) DOX releases locally, and could
directly attack tumor cells with limited systemic side effects, and (2) sustained release of
DOX causes accumulation improving effectiveness. Since the mode of delivery is quite
different between localized delivery and systemic delivery, the dose cannot be directly
compared. Additionally, the dimensions and the number of millirods could be varied to
adjust the dose.
Implants inside the body can easily encounter the circulatory system creating unexpected problems. Therefore, it is imperative to understand the role of serum proteins on
the drug release mechanism due to corona formation. We used 10% newborn calf serum
as a medium for drug release to mimic the more realistic conditions. Figure 11D shows
the release of a low and steady dose of DOX from both np-Au and np-Au@PLGA/RAPA
for 25 days. In the first 24 h, the DOX released is negligible suggesting that protein corona
forms instantly around the implants regardless of PLGA coating. After 24 h, we observed
burst release suggesting a sudden escape of DOX from a protein barrier by diffusion for 48 h,
followed by sustained release. Since DOX is gradually releasing from np-Au@PLGA/RAPA
through the PLGA matrix, we can assume that PLGA is degrading, and hence RAPA is
also releasing steadily. However, due to the extreme background signals from proteins in
serum, RAPA’s release profile could not be experimentally verified using UV–Vis.
3.8. Drug Release Kinetics
To better understand the release mechanism of DOX from np-Au and np-Au@PLGA/
RAPA and that of RAPA from np-Au@PLGA/RAPA, the drugs release profiles were
fitted with different commonly used mathematical models for drug release. The best
models were chosen based on R2 values and kinetic data are presented in Table 1. The
Korsmeyer−Peppas model best fits the release of DOX from both np-Au and np-Au@PLGA/
RAPA and RAPA from np-Au@PLGA/RAPA in the buffer at all pH. The initial 60% of the
drug release data were fitted to a semiempirical Korsmeyer–Peppas equation [75]
Mt
= k × tn
M∞
where Mt /M∞ is the drug release fraction at time t, k is the release rate constant, and n is
the release exponent that indicates the drug release mechanism.
For a non-swellable cylindrical sample, n = 4.5 corresponds to the Fickian diffusion,
4.5 < n < 1 corresponds to the anomalous (non-Fickian) transport, n = 1 corresponds to Case
II (zero-order release), and n > 1 corresponds to super Case-II diffusion [76,77]. According
to this classification, DOX released from np-Au at pH 5.5 (n = 0.47) and 6.6 (n = 0.98)
was controlled by anomalous transport. Interestingly, at a pH 5.5 value of n is so close
to 0.45 that it can be considered Fickian diffusion and at pH 6.6 value of n is so close
to 1.00 that it can be considered a zero-order release. At pH 7.4 (n = 1.14), the release
of DOX from np-Au is controlled by super Case-II diffusion. The DOX released from
np-Au@PLGA/RAPA at pH 5.5 (n = 1.08) and 6.6 (n = 1.13) is controlled by super Case-II
diffusion whereas at pH 7.4 (n = 0.84) it is controlled by anomalous transport. The value
of n obtained for RAPA released from np-Au@PLGA/RAPA at pH 5.5, 6.6, and 7.4 were
1.19, 0.69, and 0.32, respectively. This proves that pH had a significant impact on degrading
PLGA film and hence in the drug release process. The release mechanism of DOX from
np-Au@PLGA/RAPA is the super Case-II diffusion, anomalous transport, and Fickian
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diffusion at pH 5.5, 6.6, and 7.4, respectively. Unlike in buffers, the release of DOX from
both np-Au and np-Au@PLGA/RAPA in NBCS better fit the linear polynomial equation
to support the zero-order release model. This underscores the necessity of determining
the release kinetics of drugs in a medium similar to the real environment rather than just
in the buffer solution, as the release kinetics may vary substantially with the nature of
the medium.
Table 1. Kinetic parameters for DOX/RAPA release from np-Au-based implants.
Model

Release Medium
pH 5.5

KorsmeyerPeppas

pH 6.6

pH 7.4
Zero order

pH 7.4 (NBCS)

Drug

Implant

R2

n

k

DOX
DOX
RAPA
DOX
DOX
RAPA
DOX
DOX
RAPA
DOX
DOX

np-Au
np-Au@PLGA/RAPA
np-Au@PLGA/RAPA
np-Au
np-Au@PLGA/RAPA
np-Au@PLGA/RAPA
np-Au
np-Au@PLGA/RAPA
np-Au@PLGA/RAPA
np-Au
np-Au@PLGA/RAPA

0.942
0.983
0.984
0.997
0.988
0.991
0.948
0.993
0.994
0.991
0.997

0.47
1.08
1.19
0.98
1.13
0.69
1.14
0.84
0.32
NA
NA

1.66
0.10
0.22
0.28
0.07
2.28
0.19
0.27
11.09
0.04
0.03

4. Conclusions
We demonstrated that np-Au millirods possess outstanding DOX loading capacity
without any chemical modification of DOX or np-Au. We discussed the possible mechanisms of loading of DOX onto np-Au, which involve Au–π and Au–carbonyl interactions
between Au and DOX and dimerization of DOX through π–π stacking. We assumed that
sustained release of DOX from np-Au occurs only due to the breaking of π–π stacking
under the experimental conditions (37 ◦ C, pH 5.5–7.4), leaving the rest of the DOX inside
np-Au. Nearly 100% of the remaining DOX can be removed by dipping the np-Au on
DMSO for 1 h. Additionally, we identified the DOX-loaded np-Au@PLGA/RAPA as a
promising candidate for sustained co-release of RAPA and DOX, which may substantially
avoid dosage related toxicity. During co-release, the RAPA released from PLGA may
weaken the drug resistance capacity of tumor cells and therefore, the monomeric DOX
released from np-Au has a higher possibility to enter cancer cells. The advantage of this
macroscopic-sized nanostructured implant is that its dimensions can be easily varied, and
hence the dosage can possibly be delivered according to the patient’s needs. Implants
made from nanoporous gold also have the possibility for external stimulation of drug
release by illumination with an infrared laser or application of ultrasound. The size of
the implant was chosen thinking that it can be placed inside or near the tumor volume
using an implant applicator or image-guided catheter in a minimally invasive manner [78].
Additionally, np-Au can generate localized surface plasmon resonance [79], a property
that can be used for heating the surrounding of the nanostructures using a near-infrared
laser [80]. This property can be applied for increasing the release rate of drugs or directly
heat-killing cancer cells. Therefore, we need to understand the drug loading and release
behavior of np-Au for future development and improvement of the drug delivery system.
The tunability of pore size accessible by varying the dealloying conditions and also the
possibility for surface modification can provide means of varying the release profile using
implants of the same dimensions.
Supplementary Materials: The following are available online at https://www.mdpi.com/2079-499
1/11/1/208/s1, Figure S1: UV-Vis absorption spectra of DOX and RAPA, Figure S2: standard calibration plots, Figure S3: photographic image showing the importance of NaCl to prevent degradation of
DOX on np-Au surface.
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